Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.7K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

11.5K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.5K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

3.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

235
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
235
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

389
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
389
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

271
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
271

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Septic Endophthalmitis Following Suprachoroidal Cyclosporine Implant Placement in Two Horses With Equine Recurrent Uveitis.

Case reports in veterinary medicine·2026
Same author

Effect of Vibration Anesthesia on Injection-Related Pain: A Prospective Crossover Study [Response to Letter].

Journal of pain research·2026
Same author

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same author

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same author

Non-Interventional Study to Evaluate the Effect of Non-Diffractive Extended Depth of Focus Intraocular Lens Centration and Tilt on Visual Performance.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Effect of Vibration Anesthesia on Injection-Related Pain: A Prospective Crossover Study.

Journal of pain research·2026

Related Experiment Video

Updated: Aug 28, 2025

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.6K

Imeglimin in type 2 diabetes.

Jessica Huston1, Hannah Schaffner2, Logan Langley1,2

  • 1University of Florida, College of Pharmacy, Jacksonville, Florida, USA.

Drugs of Today (Barcelona, Spain : 1998)
|September 14, 2022
PubMed
Summary

Imeglimin offers a novel approach to managing type 2 diabetes by targeting multiple pathways for glycemic control. This review examines the clinical evidence for this promising new medication.

Keywords:
AMP-activated protein kinase activatorsAntidiabetic drugsGliminsGlucose-stimulated insulin secretionImegliminTetrahydrotriazine-containing antidiabeticsType 2 diabetes mellitus

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

69.1K
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K

Related Experiment Videos

Last Updated: Aug 28, 2025

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.6K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

69.1K
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (TDM) is a chronic condition marked by hyperglycemia, leading to severe microvascular and macrovascular complications.
  • Current TDM medications often address limited physiological defects and may cause side effects impacting patient adherence.
  • There is a need for novel therapeutic agents with improved efficacy and tolerability.

Purpose of the Study:

  • To review the existing clinical and scientific evidence for imeglimin, a novel first-in-class medication for TDM.
  • To discuss the unique multi-pathway mechanism of action of imeglimin in glycemic control.
  • To evaluate the potential of imeglimin as a therapeutic option for TDM management.

Main Methods:

  • Systematic review of preclinical and clinical studies on imeglimin.
  • Analysis of pharmacological data regarding imeglimin's mechanism of action.
  • Evaluation of safety and efficacy data from clinical trials.

Main Results:

  • Imeglimin demonstrates a novel mechanism targeting multiple pathways involved in glucose metabolism.
  • Clinical studies indicate imeglimin's efficacy in improving glycemic control in TDM patients.
  • The safety profile of imeglimin appears favorable, potentially improving medication adherence.

Conclusions:

  • Imeglimin represents a significant advancement in TDM treatment due to its unique multi-target mechanism.
  • The drug shows promise in effectively managing hyperglycemia and potentially reducing diabetes-related complications.
  • Further clinical investigation and real-world data are warranted to fully establish imeglimin's role in TDM therapy.